The praluent market research report is one of a series of new reports that provides praluent market statistics, including the praluent industry's global market size, regional shares, competitors with a praluent market share, detailed praluent market segments, market trends and opportunities, and any further data you may need to thrive in the praluent industry. This praluent market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The growth in the forecast period can be attributed to the increasing prevalence of cardiovascular diseases, growing awareness of hyperlipidemia management, rising demand for effective cholesterol-lowering treatments, expanding use of PCSK9 inhibitors, increasing adoption of personalized medicine, and rising healthcare investments. Major trends in the forecast period include the development of higher-dose formulations, advancements in drug delivery devices, integration with digital health technologies for remote monitoring, advancements in biotechnology, and the adoption of personalized medicine.
The increasing prevalence of cardiovascular diseases is expected to drive the growth of the Praluent market. Cardiovascular diseases encompass a range of conditions affecting the heart and blood vessels, including coronary artery disease, heart attacks, and strokes. The rise in these diseases is largely due to unhealthy lifestyle factors such as poor diet, physical inactivity, and increased use of tobacco and alcohol. Praluent helps manage cardiovascular diseases by lowering LDL cholesterol through PCSK9 inhibition, reducing the risk of heart attacks and strokes. For example, the Office for National Statistics in December 2022 reported that 3.6 million people in the UK had a cardiovascular condition, which accounted for 6.4% of the population, demonstrating the growing prevalence of these diseases and driving the demand for Praluent.
The rise in obesity is another factor contributing to the growth of the praluent market. Obesity is characterized by excessive body fat accumulation that poses a risk to health, typically defined by a Body Mass Index (BMI) of 30 or higher. The increasing prevalence of obesity is largely driven by changes in global food systems, unhealthy eating habits, sedentary lifestyles, and economic factors that make unhealthy foods more accessible. Praluent can help manage obesity-related dyslipidemia by reducing LDL cholesterol levels. As a PCSK9 inhibitor, it enhances the liver's ability to remove LDL cholesterol from the blood, improving cardiovascular health and mitigating obesity-related complications. According to a report from the Office for Health Improvement and Disparities in 2024, approximately 64% of adults aged 18 and above in England were classified as overweight or obese in 2022-2023, a slight increase from the previous year. This rise in obesity is expected to continue driving the growth of the praluent market.
An emerging trend in the praluent market is the focus on personalized medicine, particularly in the development of LDL cholesterol-lowering therapies aimed at improving the precision and effectiveness of patient care. These therapies are designed to lower LDL cholesterol, often referred to as "bad cholesterol," to reduce the risk of cardiovascular diseases such as heart attacks and strokes. In March 2024, Regeneron Pharmaceuticals Inc. received extended approval from the U.S. Food and Drug Administration (FDA) for Praluent (alirocumab) injection to treat children with a genetic form of high cholesterol. This approval allows the use of Praluent as an add-on therapy to diet and other LDL-C-lowering treatments for pediatric patients aged 8 and older with heterozygous familial hypercholesterolemia (HeFH), addressing the specific needs of children and reducing cardiovascular risks for young patients.
The key companies operating in the praluent market are Sanofi S.A., and Regeneron Pharmaceuticals Inc.
North America was the largest region in the praluent market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in praluent report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the praluent market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Praluent is a monoclonal antibody used to treat high cholesterol levels, particularly low-density lipoprotein (LDL) cholesterol, commonly referred to as bad cholesterol. It is prescribed for adults with primary hypercholesterolemia or mixed dyslipidemia and to reduce cardiovascular risk in patients with established heart disease.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The primary indications for praluent include primary hypercholesterolemia, mixed dyslipidemia, and established atherosclerotic cardiovascular disease (ASCVD). Primary hypercholesterolemia is a genetic disorder characterized by high levels of LDL cholesterol in the blood. Praluent, containing alirocumab, works by inhibiting the PCSK9 protein, which helps lower LDL cholesterol levels. It is distributed through various channels, including hospitals, clinics, retail pharmacies, and specialty pharmacies, and is used by end users such as ambulatory care and homecare patients.
The praluent market consists of sales of praluent (alirocumab) injection and one per-filled pen. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The growth in the forecast period can be attributed to the increasing prevalence of cardiovascular diseases, growing awareness of hyperlipidemia management, rising demand for effective cholesterol-lowering treatments, expanding use of PCSK9 inhibitors, increasing adoption of personalized medicine, and rising healthcare investments. Major trends in the forecast period include the development of higher-dose formulations, advancements in drug delivery devices, integration with digital health technologies for remote monitoring, advancements in biotechnology, and the adoption of personalized medicine.
The increasing prevalence of cardiovascular diseases is expected to drive the growth of the Praluent market. Cardiovascular diseases encompass a range of conditions affecting the heart and blood vessels, including coronary artery disease, heart attacks, and strokes. The rise in these diseases is largely due to unhealthy lifestyle factors such as poor diet, physical inactivity, and increased use of tobacco and alcohol. Praluent helps manage cardiovascular diseases by lowering LDL cholesterol through PCSK9 inhibition, reducing the risk of heart attacks and strokes. For example, the Office for National Statistics in December 2022 reported that 3.6 million people in the UK had a cardiovascular condition, which accounted for 6.4% of the population, demonstrating the growing prevalence of these diseases and driving the demand for Praluent.
The rise in obesity is another factor contributing to the growth of the praluent market. Obesity is characterized by excessive body fat accumulation that poses a risk to health, typically defined by a Body Mass Index (BMI) of 30 or higher. The increasing prevalence of obesity is largely driven by changes in global food systems, unhealthy eating habits, sedentary lifestyles, and economic factors that make unhealthy foods more accessible. Praluent can help manage obesity-related dyslipidemia by reducing LDL cholesterol levels. As a PCSK9 inhibitor, it enhances the liver's ability to remove LDL cholesterol from the blood, improving cardiovascular health and mitigating obesity-related complications. According to a report from the Office for Health Improvement and Disparities in 2024, approximately 64% of adults aged 18 and above in England were classified as overweight or obese in 2022-2023, a slight increase from the previous year. This rise in obesity is expected to continue driving the growth of the praluent market.
An emerging trend in the praluent market is the focus on personalized medicine, particularly in the development of LDL cholesterol-lowering therapies aimed at improving the precision and effectiveness of patient care. These therapies are designed to lower LDL cholesterol, often referred to as "bad cholesterol," to reduce the risk of cardiovascular diseases such as heart attacks and strokes. In March 2024, Regeneron Pharmaceuticals Inc. received extended approval from the U.S. Food and Drug Administration (FDA) for Praluent (alirocumab) injection to treat children with a genetic form of high cholesterol. This approval allows the use of Praluent as an add-on therapy to diet and other LDL-C-lowering treatments for pediatric patients aged 8 and older with heterozygous familial hypercholesterolemia (HeFH), addressing the specific needs of children and reducing cardiovascular risks for young patients.
The key companies operating in the praluent market are Sanofi S.A., and Regeneron Pharmaceuticals Inc.
North America was the largest region in the praluent market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in praluent report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the praluent market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Praluent is a monoclonal antibody used to treat high cholesterol levels, particularly low-density lipoprotein (LDL) cholesterol, commonly referred to as bad cholesterol. It is prescribed for adults with primary hypercholesterolemia or mixed dyslipidemia and to reduce cardiovascular risk in patients with established heart disease.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The primary indications for praluent include primary hypercholesterolemia, mixed dyslipidemia, and established atherosclerotic cardiovascular disease (ASCVD). Primary hypercholesterolemia is a genetic disorder characterized by high levels of LDL cholesterol in the blood. Praluent, containing alirocumab, works by inhibiting the PCSK9 protein, which helps lower LDL cholesterol levels. It is distributed through various channels, including hospitals, clinics, retail pharmacies, and specialty pharmacies, and is used by end users such as ambulatory care and homecare patients.
The praluent market consists of sales of praluent (alirocumab) injection and one per-filled pen. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Praluent Market Characteristics4. Praluent Market Trends And Strategies5. Praluent Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market7. Global Praluent Pricing Analysis & Forecasts30. Global Praluent Market Competitive Benchmarking And Dashboard31. Key Mergers And Acquisitions In The Praluent Market32. Recent Developments In The Praluent Market
3. Praluent Market Biologic Drug Characteristics
6. Global Praluent Growth Analysis And Strategic Analysis Framework
8. Praluent Market Segmentation
9. Global Praluent Epidemiology Of Clinical Indications
10. Praluent Market Regional And Country Analysis
11. Asia-Pacific Praluent Market
12. China Praluent Market
13. India Praluent Market
14. Japan Praluent Market
15. Australia Praluent Market
16. South Korea Praluent Market
17. Western Europe Praluent Market
18. UK Praluent Market
19. Germany Praluent Market
20. France Praluent Market
21. Eastern Europe Praluent Market
22. North America Praluent Market
23. USA Praluent Market
24. Canada Praluent Market
25. South America Praluent Market
26. Middle East Praluent Market
27. Africa Praluent Market
28. Praluent Market Competitive Landscape And Company Profiles
29. Global Praluent Market Pipeline Analysis
33. Praluent Market High Potential Countries, Segments and Strategies
34. Appendix
Executive Summary
Praluent Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on praluent market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for praluent ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The praluent market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Indication: Primary Hypercholesterolemia; Mixed Dyslipidemia; Established Atherosclerotic Cardiovascular Disease (ASCVD)2) By Distribution Channel: Hospitals And Clinics; Retail Pharmacies; Specialty Pharmacies
3) By End-User: Ambulatory Care; Home Care
Key Companies Profiled: Sanofi S.A.; Regeneron Pharmaceuticals Inc.
Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Sanofi S.A.
- Regeneron Pharmaceuticals Inc.
